Urinary Incontinence - Drug Pipeline Landscape, 2023

Urinary Incontinence - Drug Pipeline Landscape, 2023

Urinary incontinence (UI) is the involuntary leakage of urine. UI happens when the muscles in the bladder that control the flow of urine contract or relax involuntarily, resulting in leaks or uncontrolled urination.

The common causes of urinary incontinence include overactive bladder muscles, weakened pelvic floor muscles, nerve damage, interstitial cystitis (chronic bladder inflammation), obstruction, neurological disorders such as multiple sclerosis, stroke, or Parkinson's disease. Urinary incontinence may also be caused by urinary tract infection and constipation.

Urinary incontinence symptoms include leaking urine during bending, coughing, or exercising; sudden, strong urges to urinate; Leaking urine without feeling any warning sign or urge; Bed-wetting.

Diagnosis of UI include urinalysis, blood tests, pelvic ultrasound, postvoid residual (pvr) measurement, stress test, cystogram, cystoscopy and urodynamic testing.

Urinary incontinence can be treated with behavioral techniques, medications, pelvic floor muscle exercises, electrical stimulation, medical devices, interventional therapies and surgery.

There are many clinical trials currently ongoing in urinary incontinence drug development. Some of the most promising trials are studying the efficacy of botulinum toxin type A injections for the treatment of urge incontinence.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of urinary incontinence treatment such as AMDC-USR, Gefapixant, and others. Key players involved in the development of therapies to treat urinary incontinence are Cook MyoSite, Merck & Co, and others. Three drugs are under Phase III clinical trials and four drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Urinary Incontinence - Drug Pipeline Landscape, 2023 report provides an overview of the Urinary Incontinence pipeline drugs. This report covers detailed insights on Urinary Incontinence drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Urinary Incontinence pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Urinary Incontinence - Pipeline Drugs, 2023-Coverage
2. Disease Overview - Urinary Incontinence
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Urinary Incontinence - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs - Phase III
5.1.1 AMDC-USR
5.1.2 aSMDC
5.1.3 Gefapixant
5.2 Clinical Stage Drugs - Phase II
5.2.1 BAY1817080
5.2.2 Litoxetine
5.2.3 TAS-303
5.2.4 URO-902
5.3 Clinical Stage Drugs - Phase I
5.3.1 Autologous Muscle Tissue Regeneration
5.4 Early Stage Drugs - Preclinical
5.4.1 Cevaris
5.4.2 CR002
5.4.3 Drug for Urninary Incontinence
5.4.4 PEP
5.4.5 Mesenchymal Stem Cells
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Bayer
9.2 Cook MyoSite
9.3 Crystec Ltd
9.4 Exopharm Ltd
9.5 Innovacell AG
9.6 Ixaltis SA
9.7 Merck Sharp & Dohme LLC
9.8 MUVON Therapeutics AG
9.9 Orgenesis Inc
9.10 RION Health Inc
9.11 Taiho Pharmaceutical Co., Ltd.
9.12 Urovant Sciences GmbH
9.13 Versameb AG
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details - AMDC-USR/Cook MyoSite
Table 2.2 Clinical Trial Details - aSMDC/Innovacell AG
Table 2.3 Clinical Trial Details - Gefapixant/Merck Sharp & Dohme LLC
Table 2.4 Clinical Trial Details - BAY1817080/Bayer
Table 2.5 Clinical Trial Details - Litoxetine/Ixaltis SA
Table 2.6 Clinical Trial Details - TAS-303/Taiho Pharmaceutical Co., Ltd.
Table 2.7 Clinical Trial Details - URO-902/Urovant Sciences GmbH
Table 2.8 Clinical Trial Details - Autologous Muscle Tissue Regeneration/MUVON Therapeutics AG
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4. 2 Discontinued Drugs
List of Figures
Figure 1. 1 Number of Products under Development for Urinary Incontinence, 2023
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Urinary Incontinence, 2023
Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Urinary Incontinence, 2023
Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Urinary Incontinence, 2023
Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Urinary Incontinence, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings